School of Medicine, National University of Singapore, Singapore.
J Clin Oncol. 2011 Nov 20;29(33):4381-6. doi: 10.1200/JCO.2011.36.8902. Epub 2011 Oct 3.
Male breast cancer is a rare disease with an incidence rate less than 1% of that of female breast cancer. Given its low incidence, few studies have assessed risk and prognosis.
This population-based study, including 459,846 women and 2,665 men diagnosed with breast cancer in Denmark, Finland, Geneva, Norway, Singapore, and Sweden over the last 40 years, compares trends in incidence, relative survival, and relative excess mortality between the sexes.
World standardized incidence rates of breast cancer were 66.7 per 10(5) person-years in women and 0.40 per 10(5) person-years in men. Women were diagnosed at a younger median age (61.7 years) than men (69.6 years). Male patients had a poorer 5-year relative survival ratio than women (0.72 [95% CI, 0.70 to 0.75] v 0.78 [95% CI, 0.78 to 0.78], respectively), corresponding to a relative excess risk (RER) of 1.27 (95% CI, 1.13 to 1.42). However, after adjustment for age and year of diagnosis, stage, and treatment, male patients had a significantly better relative survival from breast cancer than female patients (RER, 0.78; 95% CI, 0.62 to 0.97).
Male patients with breast cancer have later onset of disease and more advanced disease than female patients. Male patients with breast cancer have lower risk of death from breast cancer than comparable female patients.
男性乳腺癌是一种罕见疾病,其发病率低于女性乳腺癌的 1%。由于发病率低,很少有研究评估其风险和预后。
本基于人群的研究纳入了过去 40 年在丹麦、芬兰、日内瓦、挪威、新加坡和瑞典诊断出患有乳腺癌的 459846 名女性和 2665 名男性,比较了男女之间发病率、相对生存率和相对超额死亡率的趋势。
女性乳腺癌的世界标准化发病率为 66.7/10(5)人年,男性为 0.40/10(5)人年。女性的中位诊断年龄(61.7 岁)低于男性(69.6 岁)。男性患者的 5 年相对生存率低于女性(0.72[95%CI,0.70 至 0.75]比 0.78[95%CI,0.78 至 0.78]),相对超额风险(RER)为 1.27(95%CI,1.13 至 1.42)。然而,在调整年龄、诊断年份、分期和治疗后,男性患者的乳腺癌相对生存率明显高于女性患者(RER,0.78;95%CI,0.62 至 0.97)。
男性乳腺癌患者的发病年龄晚,疾病分期更晚。与可比的女性患者相比,男性乳腺癌患者死于乳腺癌的风险较低。